Package Leaflet:information for the user
MicardisPlus 80mg/25mg tablets
telmisartan/hydrochlorothiazide
Read all of this leaflet carefully before you start taking this medicine, because it contains important information for you.
Contents of the pack
MicardisPlus is a combination of two active substances, telmisartan and hydrochlorothiazide, in one tablet. Both active substances help to control high blood pressure.
High blood pressure, if left untreated, can damage blood vessels in various organs, which can lead, in some cases, to heart attacks, heart failure, or renal failure, strokes, or blindness. Usually, there are no symptoms of high blood pressure before damage occurs. Therefore, it is important to regularly measure your blood pressure to verify if it is within the normal range.
MicardisPlus is used to treat high blood pressure (essential hypertension) in adults whose blood pressure is not adequately controlled with MicardisPlus 80 mg/12.5 mg or in patients who have previously been stabilized with telmisartan and hydrochlorothiazide separately.
Do not take MicardisPlus
If any of the above applies to you, inform your doctor or pharmacist before taking MicardisPlus.
Warnings and precautions
Consult your doctor before taking MicardisPlus if you have or have had any of the following disorders or diseases:
Consult your doctor before taking MicardisPlus:
Your doctor may monitor your kidney function, blood pressure, and blood electrolyte levels (e.g., potassium) at regular intervals. See also the information under the heading "Do not take MicardisPlus".
Consult your doctor if you experience abdominal pain, nausea, vomiting, or diarrhea after taking MicardisPlus. Your doctor will decide whether to continue treatment. Do not stop taking MicardisPlus on your own.
If you are pregnant, think you may be pregnant, or plan to become pregnant, inform your doctor. MicardisPlus is not recommended during pregnancy and should not be taken if you are more than 3 months pregnant, as it can cause serious harm to your baby if used at this stage (see section Pregnancy).
Treatment with hydrochlorothiazide can cause an electrolyte imbalance in your body. Typical symptoms of fluid or electrolyte imbalance include dry mouth, weakness, lethargy, somnolence, restlessness, pain or muscle cramps, nausea, vomiting, muscle fatigue, and an abnormally rapid heart rate (more than 100 beats per minute). If you experience any of these symptoms, inform your doctor.
You should also inform your doctor if you experience increased skin sensitivity to the sun with symptoms of sunburn (such as redness, itching, swelling, blistering) that appear more quickly than usual.
If you are going to undergo surgery or anesthesia, inform your doctor that you are taking MicardisPlus.
MicardisPlus may be less effective in lowering blood pressure in black patients.
Children and adolescents
MicardisPlus is not recommended for use in children and adolescents up to 18 years of age.
Other medicines and MicardisPlus
Inform your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. Your doctor may need to change the dose of these other medicines or take other precautions. In some cases, you may need to stop taking one of the medicines. This is especially applicable to the following medicines when taken with MicardisPlus:
MicardisPlus may increase the blood-pressure-lowering effect of other medicines used to treat high blood pressure or medicines that can potentially lower blood pressure (e.g., baclofen, amifostine). Additionally, the decrease in blood pressure may be enhanced by alcohol, barbiturates, narcotics, or antidepressants. You may notice this effect as dizziness when standing up. You should consult your doctor if you need to adjust the dose of your other medicines while taking MicardisPlus.
The effect of MicardisPlus may be reduced when using NSAIDs (non-steroidal anti-inflammatory drugs, e.g., aspirin or ibuprofen).
Taking MicardisPlus with food and alcohol
You can take MicardisPlus with or without food.
Avoid drinking alcohol until you have talked to your doctor. Alcohol can further lower your blood pressure and/or increase the risk of feeling dizzy or weak.
Pregnancy and breastfeeding
Pregnancy
You should inform your doctor if you are pregnant, think you may be pregnant, or plan to become pregnant. Your doctor will normally advise you to stop taking MicardisPlus before you become pregnant or as soon as you know you are pregnant, and will recommend that you take another blood pressure-lowering medicine instead. MicardisPlus is not recommended during pregnancy, and it must not be taken after the third month of pregnancy, as it may cause serious harm to your baby if taken after this point.
Breastfeeding
Inform your doctor if you are about to start or are breastfeeding, as MicardisPlus is not recommended for use in women during this period. Your doctor may decide to prescribe you a different treatment if you want to breastfeed.
Driving and using machines
Some people feel dizzy, faint, or feel like everything is spinning when taking MicardisPlus. If you experience any of these effects, do not drive or use machines.
MicardisPlus contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per tablet; this is essentially "sodium-free".
MicardisPlus contains lactose
If your doctor has told you that you have an intolerance to some sugars, consult them before taking this medicine.
MicardisPlus contains sorbitol
This medicine contains 338 mg of sorbitol in each tablet. Sorbitol is a source of fructose. If your doctor has told you that you have an intolerance to some sugars, or you have been diagnosed with hereditary fructose intolerance (HFI), a rare genetic disorder in which the patient cannot break down fructose, consult your doctor before taking this medicine.
Take this medicine exactly as your doctor has told you. If you are not sure, ask your doctor or pharmacist.
The recommended dose is one tablet per day. Try to take the tablet at the same time each day. You can take MicardisPlus with or without food. The tablets should be swallowed whole with a little water or other non-alcoholic drink. It is important that you take MicardisPlus every day until your doctor tells you to stop.
If your liver is not working properly, the usual dose should not exceed 40 mg of telmisartan once a day.
If you take more MicardisPlus than you should
If you accidentally take too many tablets, you may experience symptoms such as low blood pressure and rapid heartbeat. Slow heartbeat, dizziness, vomiting, and reduced kidney function, including kidney failure, have also been reported. Due to the hydrochlorothiazide component, you may also experience very low blood pressure and low potassium levels in the blood, which can lead to nausea, somnolence, and muscle cramps and/or irregular heartbeat associated with the simultaneous use of medicines like digitalis or certain antiarrhythmic treatments. Contact your doctor or pharmacist or the nearest hospital emergency department immediately.
If you forget to take MicardisPlus
If you forget to take a dose, do not worry. Take it as soon as you remember and continue as before. If you do not take your tablet one day, take your normal dose the next day. Donottake a double dose to make up for forgotten doses.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
Some adverse effects can be serious and require immediate medical attention:
If you experience any of the following symptoms, you should visit your doctor immediately:
Sepsis* (frequently called "blood infection", a serious infection that involves an inflammatory reaction of the entire body), rapid swelling of the skin and mucous membranes (angioedema including fatal outcome), blistering and peeling of the outer layer of the skin (toxic epidermal necrolysis); these adverse effects are rare (may affect up to 1 in 1,000 people) or very rare (toxic epidermal necrolysis; may affect up to 1 in 10,000 people), but are extremely serious and patients should stop taking the medicine and visit their doctor immediately. If these adverse effects are not treated, they can be fatal. An increase in the incidence of sepsis has been observed with telmisartan alone; however, it cannot be ruled out for MicardisPlus.
Possible Adverse Effects of MicardisPlus:
Common Adverse Effects (may affect up to 1 in 10 people)
Dizziness.
Uncommon Adverse Effects (may affect up to 1 in 100 people)
Decrease in potassium levels in the blood, anxiety, fainting (syncope), tingling sensation, numbness (paresthesia), sensation that everything is spinning (vertigo), rapid heartbeat (tachycardia), heart rhythm disturbances, low blood pressure, sudden decrease in blood pressure when standing up, shortness of breath (dyspnea), diarrhea, dry mouth, flatulence, back pain, muscle spasms, muscle pain, erectile dysfunction (inability to have or maintain an erection), chest pain, and increased levels of uric acid in the blood.
Rare Adverse Effects (may affect up to 1 in 1,000 people)
Inflammation of the airways leading to the lungs (bronchitis), sore throat, inflammation of the paranasal sinuses, increased levels of uric acid, low sodium levels, feeling of sadness (depression), difficulty falling asleep (insomnia), sleep disorder, vision disturbance, blurred vision, breathing difficulties, abdominal pain, constipation, abdominal distension (dyspepsia), nausea (vomiting), stomach inflammation (gastritis), liver function disturbance (Japanese patients show a greater tendency to experience this adverse effect), redness of the skin (erythema), allergic reactions such as itching or rash, increased sweating, hives (urticaria), joint pain (arthralgia), and pain in the limbs (pain in the legs), muscle cramps, activation or worsening of systemic lupus erythematosus (a disease in which the body's immune system attacks the body itself, causing joint pain, skin rashes, and fever), pseudo-flu syndrome, pain, increased levels of creatinine, liver enzymes, or creatine phosphokinase in the blood.
Adverse reactions reported for one of the individual components may be potential adverse reactions of MicardisPlus, even if they have not been observed in clinical trials with this product.
Telmisartan
The following additional adverse effects have been reported in patients taking telmisartan alone:
Uncommon Adverse Effects (may affect up to 1 in 100 people)
Upper respiratory tract infection (e.g., sore throat, paranasal sinus inflammation, common cold), urinary tract infections, bladder infection, low red blood cell count (anemia), high potassium levels, slow heart rate (bradycardia), cough, kidney function disturbance including acute renal failure, weakness.
Rare Adverse Effects (may affect up to 1 in 1,000 people)
Low platelet count (thrombocytopenia), increased levels of certain white blood cells (eosinophilia), severe allergic reactions (e.g., hypersensitivity, anaphylactic reactions), low blood sugar levels (in diabetic patients), drowsiness, stomach upset, eczema (a skin disorder), drug rash, toxic skin rash, tendon pain (symptoms of pseudo-tendinitis), decrease in hemoglobin (a blood protein).
Very Rare Adverse Effects (may affect up to 1 in 10,000 people)
Progressive lung tissue fibrosis (interstitial lung disease)**
Frequency Not Known (cannot be estimated from the available data)
Intestinal angioedema: swelling in the intestine has been reported, which occurs with symptoms such as abdominal pain, nausea, vomiting, and diarrhea after using similar products.
** Cases of progressive lung tissue fibrosis have been reported during telmisartan treatment. However, it is unknown whether telmisartan was the cause.
Hydrochlorothiazide
The following additional adverse effects have been reported in patients taking hydrochlorothiazide alone:
Very Common Adverse Effects (may affect up to 1 in 10 people)
High levels of fats in the blood.
Common Adverse Effects (may affect up to 1 in 10 people)
Nausea, low magnesium levels in the blood, decreased appetite.
Uncommon Adverse Effects (may affect up to 1 in 100 people)
Acute renal failure.
Rare Adverse Effects (may affect up to 1 in 1,000 people)
Low platelet count (thrombocytopenia), which increases the risk of bleeding and bruising (small purple-red spots on the skin or other tissues caused by bleeding), high calcium levels in the blood, high blood sugar levels, headache, abdominal discomfort, yellowing of the skin or eyes (jaundice), excess bile salts in the blood (cholestasis), photosensitivity reaction, uncontrolled blood sugar levels in patients with a diagnosis of diabetes mellitus, sugar in the urine (glucosuria).
Very Rare Adverse Effects (may affect up to 1 in 10,000 people)
Abnormal breakdown of red blood cells (hemolytic anemia), inability of the bone marrow to function properly, reduction in white blood cells (leukopenia, agranulocytosis), severe allergic reactions (e.g., hypersensitivity), increased pH due to low chloride levels in the blood (acid-base imbalance, hypochloremic alkalosis), acute respiratory distress (signs include severe shortness of breath, fever, weakness, and confusion), pancreatitis, pseudo-lupus syndrome (a disorder that resembles a disease called systemic lupus erythematosus in which the body's immune system attacks the body itself), blood vessel inflammation (necrotizing vasculitis).
Frequency Not Known (cannot be estimated from the available data)
Skin and lip cancer (non-melanoma skin cancer), blood cell deficiency (aplastic anemia), vision loss and eye pain (possible signs of fluid accumulation in the vascular layer of the eye [choroidal effusion] or acute angle-closure glaucoma), skin disorders such as blood vessel inflammation of the skin, increased sensitivity to sunlight, skin rash, skin redness, blistering of the lips, eyes, or mouth, skin peeling, fever (possible signs of erythema multiforme), weakness, kidney function disturbance.
In isolated cases, low sodium levels have been reported, accompanied by symptoms related to the brain or nerves (nausea, progressive disorientation, lack of interest or energy).
Reporting Adverse Effects
If you experience any adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect not listed in this leaflet. You can also report them directly through the national reporting system included in Appendix V. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date stated on the carton after "EXP". The expiry date is the last day of the month indicated.
This medicine does not require any special storage temperature. Store in the original packaging to protect from moisture. Remove your MicardisPlus tablet from the sealed blister pack just before taking it.
Occasionally, the outer layer of the blister pack may separate from the inner layer between the blister pack cavities. If this is detected, no action is required on your part.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
MicardisPlus Composition
Each tablet contains 80 mg of telmisartan and 25 mg of hydrochlorothiazide.
Product Appearance and Package Contents
MicardisPlus 80 mg/25 mg tablets are oblong, two-layer tablets, yellow and white, with the company anagram and the code 'H9' engraved.
MicardisPlus is available in blister packs containing 14, 28, 56, or 98 tablets, or in single-dose blister packs containing 28 x 1, 30 x 1, or 90 x 1 tablets.
Not all pack sizes may be marketed in your country.
Marketing Authorization Holder and Manufacturer
Boehringer Ingelheim International GmbH Boehringer Ingelheim Hellas Single
Binger Str. 173 Member S.A.
55216 Ingelheim am Rhein 5th km Paiania-Markopoulo
Germany Koropi Attiki, 19441
Greece
and
Rottendorf Pharma GmbH
Ostenfelder Strasse 51 - 61
59320 Ennigerloh
Germany
and
Boehringer Ingelheim France
100-104 Avenue de France
75013 Paris
France
You can obtain more information about this medicine by contacting the local representative of the marketing authorization holder:
Belgium/België/Belgien Boehringer Ingelheim SCommTel/Tel: +32 2 773 33 11 | Lithuania Boehringer Ingelheim RCV GmbH & Co KG Lithuanian branch Tel.: +370 5 2595942 |
????????? ????????? ??? ???? ? ??. ?? - ???? ???????? ???: +359 2 958 79 98 | Luxembourg/Luxemburg Boehringer Ingelheim SCommTel/Tel: +32 2 773 33 11 |
Czech Republic Boehringer Ingelheim spol. s r.o. Tel: +420 234 655 111 | Hungary Boehringer Ingelheim RCV GmbH & Co KG Hungarian branch Tel.: +36 1 299 89 00 |
Denmark Boehringer Ingelheim Danmark A/S Tlf.: +45 39 15 88 88 | Malta Boehringer Ingelheim Ireland Ltd. Tel: +353 1 295 9620 |
Germany Boehringer Ingelheim Pharma GmbH & Co. KG Tel: +49 (0) 800 77 90 900 | Netherlands Boehringer Ingelheim B.V. Tel: +31 (0) 800 22 55 889 |
Estonia Boehringer Ingelheim RCV GmbH & Co KG Estonian branch Tel: +372 612 8000 | Norway Boehringer Ingelheim Danmark Norwegian branch Tlf: +47 66 76 13 00 |
Greece Boehringer Ingelheim Ελλ?ς Μονοπρ?σωπη Α.Ε. Tηλ: +30 2 10 89 06 300 | Austria Boehringer Ingelheim RCV GmbH & Co KG Tel: +43 1 80 105-7870 |
Spain Boehringer Ingelheim España, S.A. Tel: +34 93 404 51 00 | Poland Boehringer Ingelheim Sp. z o.o. Tel.: +48 22 699 0 699 |
France Boehringer Ingelheim France S.A.S. Tél: +33 3 26 50 45 33 | Portugal Boehringer Ingelheim Portugal, Lda. Tel: +351 21 313 53 00 |
Croatia Boehringer Ingelheim Zagreb d.o.o. Tel: +385 1 2444 600 | Romania Boehringer Ingelheim RCV GmbH & Co KG Viena - Bucharest branch Tel: +40 21 302 28 00 |
Ireland Boehringer Ingelheim Ireland Ltd. Tel: +353 1 295 9620 | Slovenia Boehringer Ingelheim RCV GmbH & Co KG Ljubljana branch Tel: +386 1 586 40 00 |
Iceland Vistor ehf. Sími: +354 535 7000 | Slovakia Boehringer Ingelheim RCV GmbH & Co KG organizational unit Tel: +421 2 5810 1211 |
Italy Boehringer Ingelheim Italia S.p.A. Tel: +39 02 5355 1 | Finland Boehringer Ingelheim Finland Ky Puh/Tel: +358 10 3102 800 |
Cyprus Boehringer Ingelheim Ελλ?ς Μονοπρ?σωπη Α.Ε. Tηλ: +30 2 10 89 06 300 | Sweden Boehringer Ingelheim AB Tel: +46 8 721 21 00 |
Latvia Boehringer Ingelheim RCV GmbH & Co KG Latvian branch Tel: +371 67 240 011 |
Date of Last Revision of this Leaflet:
Other Sources of Information
Detailed information on this medicine is available on the European Medicines Agency website: https://www.ema.europa.eu.
The average price of MICARDISPLUS 80 mg/25 mg TABLETS in October, 2025 is around 19.36 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.